Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    William Sandborn

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0956
    CA La Jolla 92093
    Phone858-657-5331
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Fellowship1993Mayo Clinic
      Intern/Residency1990Loma Linda Univ Medical Center
      MD1987Loma Linda University
      BA1983Southern College

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Jairath V, Zou G, Parker CE, MacDonald JK, Mosli MH, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Kherad O, Koutsoumpas A, Minas E, Restellini S, Samaan MA, Khanna R, Levesque BG, D'Haens G, Sandborn W, Feagan BG. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Aliment Pharmacol Ther. 2017 Feb 05. PMID: 28164348.
        View in: PubMed
      2. Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn W, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 Jan 11. PMID: 28074618.
        View in: PubMed
      3. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn W, Rutgeerts P, McDonald JW, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 Jan 10. PMID: 28071654.
        View in: PubMed
      4. Cotter TG, Gathaiya N, Catania J, Loftus EV, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn W, Limper AH, Pardi DS. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol. 2016 Dec 21. PMID: 28013116.
        View in: PubMed
      5. Cotter TG, Binder M, Loftus EV, Abboud R, McNally MA, Smyrk TC, Tremaine WJ, Sandborn W, Pardi DS. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2016 Dec 13. PMID: 27965284.
        View in: PubMed
      6. Fumery M, Dulai PS, Meirick P, Farrell AM, Ramamoorthy S, Sandborn W, Singh S. Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2016 Dec 08. PMID: 27928830.
        View in: PubMed
      7. Sands BE, Sandborn W, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2016 Dec 07. PMID: 27930408.
        View in: PubMed
      8. Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn W, Singh S. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients with Ulcerative Colitis with Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016 Dec 01. PMID: 27916678.
        View in: PubMed
      9. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn W. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2016 Nov 30. PMID: 27899815.
        View in: PubMed
      10. Feagan BG, Sandborn W, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 Nov 17; 375(20):1946-1960. PMID: 27959607.
        View in: PubMed
      11. Colombel JF, Jharap B, Sandborn W, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2016 Nov 7. PMID: 27883215.
        View in: PubMed
      12. Ghosh S, Sandborn W, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 Nov; 22(11):2711-2723. PMID: 27585411.
        View in: PubMed
      13. Hindryckx P, Levesque BG, Holvoet T, Durand S, Tang CM, Parker C, Khanna R, Shackelton LM, D'Haens G, Sandborn W, Feagan BG, Lebwohl B, Leffler DA, Jairath V. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2016 Oct 31. PMID: 27799282.
        View in: PubMed
      14. Arulanandan A, Dulai PS, Singh S, Sandborn W, Kalmaz D. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016 Oct 28; 22(40):8999-9011. PMID: 27833391.
        View in: PubMed
      15. Siegel CA, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DP, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. Gut. 2016 Oct 25. PMID: 27780886.
        View in: PubMed
      16. Abraham C, Dulai PS, Vermeire S, Sandborn W. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2016 Oct 22. PMID: 27780712.
        View in: PubMed
      17. Reinisch W, Colombel JF, D'Haens G, Sandborn W, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. J Crohns Colitis. 2016 Oct 10. PMID: 27815351.
        View in: PubMed
      18. Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn W, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2016 Sep 28. PMID: 27683798.
        View in: PubMed
      19. Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn W, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2016 Sep 28. PMID: 27683800.
        View in: PubMed
      20. Osterman MT, Sandborn W, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016 Dec; 111(12):1806-1815. PMID: 27670599.
        View in: PubMed
      21. Dulai PS, Sandborn W, Gupta S. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016 Dec; 9(12):887-894. PMID: 27679553.
        View in: PubMed
      22. Peyrin-Biroulet L, Lopez A, Sandborn W. Head-to-head comparative studies: Challenges & opportunities? J Crohns Colitis. 2016 Sep 22. PMID: 27660343.
        View in: PubMed
      23. Dulai PS, Sandborn W. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2016 Sep; 18(9):51. PMID: 27461274.
        View in: PubMed
      24. Sandborn W, Feagan BG. Ozanimod Treatment for Ulcerative Colitis. N Engl J Med. 2016 Aug 25; 375(8):e17. PMID: 27557326.
        View in: PubMed
      25. Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn W. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin. 2016 Dec; 32(12):1937-1941. PMID: 27494777.
        View in: PubMed
      26. Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn W, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016; 8:CD010642. PMID: 27501379.
        View in: PubMed
      27. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvenstein M, Rimola J, Panes J, D'Haens G, Sandborn W, Feagan BG. Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2016 Aug 3. PMID: 27487793.
        View in: PubMed
      28. Lee SD, Rubin DT, Sandborn W, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 Aug; 22(8):1870-80. PMID: 27400222.
        View in: PubMed
      29. Bosworth BP, Sandborn W, Rubin DT, Harper JR. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 Aug; 22(8):1881-6. PMID: 27416045.
        View in: PubMed
      30. Sandborn W, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 Sep; 14(9):e121-2. PMID: 27464592.
        View in: PubMed
      31. Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn W. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2016 Jul 20. PMID: 27440869.
        View in: PubMed
      32. Dubcenco E, Zou G, Stitt L, Baker JP, Jeejeebhoy KN, Kandel G, Kim YI, Grover SC, McDonald JW, Shackelton LM, Khanna R, D'Haens G, Sandborn W, Feagan BG, Levesque BG. Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. J Crohns Colitis. 2016 Sep; 10(9):1006-14. PMID: 27385400.
        View in: PubMed
      33. Sandborn W. The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7):438-41. PMID: 27489526.
        View in: PubMed
      34. Khanna R, Chande N, Vermeire S, Sandborn W, Parker CE, Feagan BG. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2016 Jul; 22(7):1737-43. PMID: 27306074.
        View in: PubMed
      35. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn W, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 Jun 14. PMID: 27296941.
        View in: PubMed
      36. Sandborn W, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016 Jul; 44(2):157-69. PMID: 27218676.
        View in: PubMed
      37. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn W, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 Sep; 14(9):1302-9. PMID: 27189916.
        View in: PubMed
      38. Sandborn W, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 5; 374(18):1754-62. PMID: 27144850.
        View in: PubMed
      39. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn W, Loftus EV. Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 Oct; 14(10):1439-44. PMID: 27155552.
        View in: PubMed
      40. Boland BS, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L, Sandborn W, Harismendy O, Gupta S. Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. Am J Gastroenterol. 2016 May; 111(5):746-8. PMID: 27151126.
        View in: PubMed
      41. Gibson PR, Feagan BG, Sandborn W, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016; 7:e168. PMID: 27124701.
        View in: PubMed
      42. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn W. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. PMID: 26835982.
        View in: PubMed
      43. Sandborn W, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 Jul; 32(7):1233-41. PMID: 26986449.
        View in: PubMed
      44. Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn W, D'Haens G, Feagan BG. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 May; 150(5):1056-60. PMID: 27018491.
        View in: PubMed
      45. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn W, Sorrentino D, Rutgeerts P. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-78. PMID: 26946343.
        View in: PubMed
      46. Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, Sands B, Hanauer S, Feagan B, Targan S, Ghosh S, de Villiers W, Colombel JF, Lee S, Desreumaux P, Loftus E, Vermeire S, Rutgeerts P. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNa: UNITI-1. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S1. PMID: 26849718.
        View in: PubMed
      47. Jharap B, Colombel JF, Sandborn W. Reply. Gastroenterology. 2016 Apr; 150(4):1039. PMID: 26926449.
        View in: PubMed
      48. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016 Feb 18. PMID: 26893500.
        View in: PubMed
      49. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. PMID: 26850690.
        View in: PubMed
      50. Ley K, Rivera-Nieves J, Sandborn W, Shattil S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016 Mar; 15(3):173-83. PMID: 26822833.
        View in: PubMed
      51. Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn W, Feagan BG. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016 May; 10(5):607-18. PMID: 26746169.
        View in: PubMed
      52. Sandborn W, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis. 2016 Apr; 10(4):418-28. PMID: 26721935.
        View in: PubMed
      53. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn W, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2015 Dec 08. PMID: 26646934.
        View in: PubMed
      54. Chande N, Marshall JK, Seow CH, Sandborn W, Parker CE, Nelson S, Feagan BG. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflamm Bowel Dis. 2015 Dec; 21(12):2948-57. PMID: 26540276.
        View in: PubMed
      55. Reiss M, Sandborn W. The Role of Psychosocial Care in Adapting to Health Care Reform. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2219-24. PMID: 26589873.
        View in: PubMed
      56. Singh S, Stroud AM, Holubar SD, Sandborn W, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015; 11:CD001176. PMID: 26593456.
        View in: PubMed
      57. Coimbra AJ, Rimola J, O'Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL, Sandborn W, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J. Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. Aliment Pharmacol Ther. 2016 Jan; 43(1):61-72. PMID: 26548868.
        View in: PubMed
      58. Boland BS, Dulai PS, Chang M, Sandborn W, Levesque BG. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. PMID: 26618431.
        View in: PubMed
      59. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn W, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. Association Between Response to Etrolizumab and Expression of Integrin aE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):477-487.e9. PMID: 26522261.
        View in: PubMed
      60. Mosli MH, Feagan BG, Zou G, Sandborn W, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. Development and validation of a histological index for UC. Gut. 2017 Jan; 66(1):50-58. PMID: 26475633.
        View in: PubMed
      61. Gottlieb K, Travis S, Feagan B, Hussain F, Sandborn W, Rutgeerts P. Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflamm Bowel Dis. 2015 Oct; 21(10):2475-82. PMID: 26086596.
        View in: PubMed
      62. Feagan BG, Sandborn W, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Aliment Pharmacol Ther. 2015 Nov; 42(10):1170-81. PMID: 26400458.
        View in: PubMed
      63. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn W, Feagan BG, Levesque BG. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015 Nov; 42(10):1200-10. PMID: 26388424.
        View in: PubMed
      64. Rubin DT, Sandborn W, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17. PMID: 26386854.
        View in: PubMed
      65. Sandborn W, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016 Jan; 150(1):96-102. PMID: 26376350.
        View in: PubMed
      66. Vuitton L, Marteau P, Sandborn W, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 2016 Sep; 65(9):1447-55. PMID: 26353983.
        View in: PubMed
      67. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn W, Donner A, Vandervoort MK, Morris JC, Feagan BG. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 7; 386(10006):1825-34. PMID: 26342731.
        View in: PubMed
      68. Jharap B, Sandborn W, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015 Nov; 42(9):1082-92. PMID: 26381802.
        View in: PubMed
      69. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. PMID: 26303131.
        View in: PubMed
      70. Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL, Sandborn W, Loftus EV. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. Aliment Pharmacol Ther. 2015 Oct; 42(7):783-92. PMID: 26264359.
        View in: PubMed
      71. Sandborn W, Bouguen G. Reply. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2382. PMID: 26247165.
        View in: PubMed
      72. Rutgeerts P, Reinisch W, Colombel JF, Sandborn W, D'Haens G, Petersson J, Zhou Q, Iezzi A, Thakkar RB. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016 Jan; 83(1):188-197.e3. PMID: 26234693.
        View in: PubMed
      73. Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR, Sandborn W. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015 Sep; 42(5):504-14. PMID: 26119226.
        View in: PubMed
      74. Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn W. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep; 9(9):738-46. PMID: 26094251.
        View in: PubMed
      75. Vande Casteele N, Sandborn W. IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. PMID: 26077557.
        View in: PubMed
      76. Peyrin-Biroulet L, Panés J, Sandborn W, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. PMID: 26071941.
        View in: PubMed
      77. Sandborn W, Melmed GY, McGovern DP, Loftus EV, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug; 42(3):330-42. PMID: 26031921.
        View in: PubMed
      78. Vaughn BP, Sandborn W, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1435-42. PMID: 25590953.
        View in: PubMed
      79. Panaccione R, Sandborn W, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. PMID: 25989338.
        View in: PubMed
      80. Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn W. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015 Aug; 82(2):246-55. PMID: 26005012.
        View in: PubMed
      81. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn W, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul; 42(2):188-202. PMID: 25996351.
        View in: PubMed
      82. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn W, Feagan BG. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110(6):802-19; quiz 820. PMID: 25964225.
        View in: PubMed
      83. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn W. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. PMID: 25956538.
        View in: PubMed
      84. Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn W, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 2016 Jul; 65(7):1119-25. PMID: 25935574.
        View in: PubMed
      85. Sandborn W. New Targets for Small Molecules in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 May; 11(5):338-40. PMID: 27482177.
        View in: PubMed
      86. Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn W, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. J Crohns Colitis. 2015 Aug; 9(8):601-6. PMID: 25908718.
        View in: PubMed
      87. Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn W, Laveille C, Oliver R. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015 Aug; 55(8):866-74. PMID: 25735646.
        View in: PubMed
      88. Reinhard A, Sandborn W, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L. Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. Expert Rev Clin Immunol. 2015 May; 11(5):637-57. PMID: 25837708.
        View in: PubMed
      89. Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn W, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015 Apr; 35(4):412-23. PMID: 25884529.
        View in: PubMed
      90. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn W. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015 Apr; 41(8):734-46. PMID: 25728587.
        View in: PubMed
      91. Bouguen G, Sninsky C, Tang KL, Colombel JF, D'Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C, Sandborn W. Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing: A Post hoc Analysis from SONIC. Inflamm Bowel Dis. 2015 Mar; 21(3):606-14. PMID: 25581826.
        View in: PubMed
      92. Lichtenstein GR, Hanauer SB, Sandborn W. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. PMID: 26491415.
        View in: PubMed
      93. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn W, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015 Mar 5; 519(7541):57-62. PMID: 25731159.
        View in: PubMed
      94. Bryant RV, Sandborn W, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis. 2015 Apr; 9(4):356-66. PMID: 25687206.
        View in: PubMed
      95. Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn W, Murray JA, Harismendy O, Chang JT. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. PMID: 25667416.
        View in: PubMed
      96. Boland BS, Boyle DL, Sandborn W, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of Gene Expression Biomarker Analysis for Biopsy-based Clinical Trials in Crohn's Disease. Inflamm Bowel Dis. 2015 Feb; 21(2):323-30. PMID: 25545378.
        View in: PubMed
      97. Sandborn W, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015 Apr; 148(4):740-750.e2. PMID: 25644096.
        View in: PubMed
      98. Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn W, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015 May; 47(5):356-64. PMID: 25661014.
        View in: PubMed
      99. Sandborn W, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015 Mar; 41(5):409-18. PMID: 25588902.
        View in: PubMed
      100. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn W, Casteele NV. Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. PMID: 25222660.
        View in: PubMed
      101. Sandborn W. Tailoring treatment to the individual patient: drug monitoring. Dig Dis. 2014; 32 Suppl 1:88-91. PMID: 25531358.
        View in: PubMed
      102. Akobeng AA, Sandborn W, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. Tumor necrosis factor-alpha antagonists twenty years later: what do cochrane reviews tell us? Inflamm Bowel Dis. 2014 Nov; 20(11):2132-41. PMID: 25299543.
        View in: PubMed
      103. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn W, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. PMID: 25192499.
        View in: PubMed
      104. Mojtahed A, Khanna R, Sandborn W, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014 Nov; 20(11):2092-103. PMID: 25137418.
        View in: PubMed
      105. Mosli MH, Feagan BG, Zou G, Sandborn W, D'Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, MacDonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG. Reproducibility of histological assessments of disease activity in UC. Gut. 2015 Nov; 64(11):1765-73. PMID: 25360036.
        View in: PubMed
      106. Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn W, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther. 2015 Jan; 41(1):77-86. PMID: 25348809.
        View in: PubMed
      107. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn W, Vermeire S, Feagan BG. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015 Oct; 64(10):1539-45. PMID: 25336114.
        View in: PubMed
      108. D'Haens G, Sandborn W, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG. A phase II study of laquinimod in Crohn's disease. Gut. 2015 Aug; 64(8):1227-35. PMID: 25281416.
        View in: PubMed
      109. Khanna R, Bouguen G, Feagan BG, D'Haens G, Sandborn W, Dubcenco E, Baker KA, Levesque BG. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014 Oct; 20(10):1850-61. PMID: 25029615.
        View in: PubMed
      110. Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF, Cosnes J. Development of the lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology. 2015 Jan; 148(1):52-63.e3. PMID: 25241327.
        View in: PubMed
      111. Reinisch W, Colombel JF, Sandborn W, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F. Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn's Disease. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):539-547.e2. PMID: 25245629.
        View in: PubMed
      112. Adedokun OJ, Sandborn W, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014 Dec; 147(6):1296-1307.e5. PMID: 25173754.
        View in: PubMed
      113. Colombel JF, Sandborn W, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov; 109(11):1771-80. PMID: 25155227.
        View in: PubMed
      114. Sandborn W, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct; 40(8):903-16. PMID: 25146586.
        View in: PubMed
      115. Levesque BG, Sandborn W, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015 Jan; 148(1):37-51.e1. PMID: 25127678.
        View in: PubMed
      116. Yadav S, Dave M, Edakkanambeth Varayil J, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sweetser SR, Melton LJ, Sandborn W, Loftus EV. A Population-based Study of Incidence, Risk Factors, Clinical Spectrum, and Outcomes of Ischemic Colitis. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):731-738.e6. PMID: 25130936.
        View in: PubMed
      117. Samaan MA, Mosli MH, Sandborn W, Feagan BG, D'Haens GR, Dubcenco E, Baker KA, Levesque BG. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014 Aug; 20(8):1465-71. PMID: 24831558.
        View in: PubMed
      118. Sandborn W. Crohn's disease evaluation and treatment: clinical decision tool. Gastroenterology. 2014 Sep; 147(3):702-5. PMID: 25046160.
        View in: PubMed
      119. Wolf D, D'Haens G, Sandborn W, Colombel JF, Van Assche G, Robinson AM, Lazar A, Zhou Q, Petersson J, Thakkar RB. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):486-97. PMID: 25041859.
        View in: PubMed
      120. Boland BS, Boyle DL, Sandborn W, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Chang JT. Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):477-85. PMID: 25041724.
        View in: PubMed
      121. Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P, Sandborn W, Sands BE. Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4. PMID: 24989100.
        View in: PubMed
      122. Dulai PS, Siegel CA, Colombel JF, Sandborn W, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor a agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014 Dec; 63(12):1843-53. PMID: 24970900.
        View in: PubMed
      123. Boland BS, Sandborn W, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014 Sep; 43(3):603-17. PMID: 25110261.
        View in: PubMed
      124. Vande Casteele N, Sandborn W. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1894-6. PMID: 24951843.
        View in: PubMed
      125. Chang JT, Sandborn W, Ernst PB. Studies in human intestinal tissues: is it time to reemphasize research in human immunology? Gastroenterology. 2014 Jul; 147(1):26-30. PMID: 24877864.
        View in: PubMed
      126. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn W, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3. PMID: 24859203.
        View in: PubMed
      127. Mosli MH, Sandborn W, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014 Jul; 109(7):994-1004. PMID: 24842338.
        View in: PubMed
      128. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn W, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26; 384(9940):309-18. PMID: 24814090.
        View in: PubMed
      129. Sandborn W, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep 1; 8(9):927-35. PMID: 24713173.
        View in: PubMed
      130. Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn W, Levesque BG. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr; 16(4):378. PMID: 24595615.
        View in: PubMed
      131. Levesque BG, Greenberg GR, Zou G, Sandborn W, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1126-35. PMID: 24689499.
        View in: PubMed
      132. Pola S, Santillan C, Levesque BG, Feagan BG, Sandborn W. An Overview of Magnetic Resonance Enterography for Crohn's Disease. Dig Dis Sci. 2014 Mar 23. PMID: 24659238.
        View in: PubMed
      133. Mosli MH, Feagan BG, Sandborn W, D'haens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014 Mar; 20(3):564-75. PMID: 24412993.
        View in: PubMed
      134. Pola S, Boland BS, Lin GY, Kuo A, Sandborn W. Non-cirrhotic Portal Hypertension Due to 6-Mercaptopurine Use for Crohn's Disease. Dig Dis Sci. 2014 Jul; 59(7):1642-4. PMID: 24535249.
        View in: PubMed
      135. Williet N, Sandborn W, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1246-1256.e6. PMID: 24534550.
        View in: PubMed
      136. Egan LJ, Sandborn W. Taking a closer look at IBD. Gut. 2014 Feb; 63(2):e1. PMID: 24381262.
        View in: PubMed
      137. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn W. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014 Feb; 20(2):231-9. PMID: 24351660.
        View in: PubMed
      138. Sandborn W, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1485-1493.e2. PMID: 24480677.
        View in: PubMed
      139. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn W. Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23. PMID: 24394749.
        View in: PubMed
      140. Osterman MT, Sandborn W, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014 Apr; 146(4):941-949.e2. PMID: 24361468.
        View in: PubMed
      141. Patel NS, Pola S, Muralimohan R, Zou GY, Santillan C, Patel D, Levesque BG, Sandborn W. Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease. Dig Dis Sci. 2014 Apr; 59(4):838-49. PMID: 24323180.
        View in: PubMed
      142. Khanna R, Levesque BG, Sandborn W. IBD: Measuring what counts-endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol. 2014 Jan; 11(1):9-10. PMID: 24296581.
        View in: PubMed
      143. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn W. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Jun; 12(6):978-85. PMID: 24246770.
        View in: PubMed
      144. Colombel JF, Sandborn W, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):423-431.e1. PMID: 24184736.
        View in: PubMed
      145. Bouguen G, Evans E, Sandborn W. Azathioprine-induced neuro-psychiatric disorders. J Crohns Colitis. 2014 Feb 1; 8(2):180. PMID: 24103346.
        View in: PubMed
      146. Panaccione R, Colombel JF, Sandborn W, D'Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013 Nov; 38(10):1236-47. PMID: 24134498.
        View in: PubMed
      147. Feagan BG, Sandborn W, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):110-118.e3. PMID: 24067881.
        View in: PubMed
      148. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn W. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. PMID: 24036054.
        View in: PubMed
      149. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn W. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014 Jan; 63(1):88-95. PMID: 23974954.
        View in: PubMed
      150. Rogler G, Sandborn W. Is there still a role for thiopurines in Crohn's disease? Gastroenterology. 2013 Oct; 145(4):714-6. PMID: 23973853.
        View in: PubMed
      151. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn W, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710. PMID: 23964932.
        View in: PubMed
      152. Sandborn W, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. PMID: 23964933.
        View in: PubMed
      153. Ferrante M, Colombel JF, Sandborn W, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013 Nov; 145(5):978-986.e5. PMID: 23954314.
        View in: PubMed
      154. Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, Tremaine WJ, Sandborn W, Loftus EV. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013 Aug; 19(9):1858-66. PMID: 23660997.
        View in: PubMed
      155. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn W. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95. PMID: 23891974.
        View in: PubMed
      156. Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn W, Feagan BG. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Sep; 38(5):447-59. PMID: 23848220.
        View in: PubMed
      157. Colombel JF, Rutgeerts PJ, Sandborn W, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):414-422.e5. PMID: 23856361.
        View in: PubMed
      158. Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn W. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis. 2013 Jul; 19(8):1645-53. PMID: 23598817.
        View in: PubMed
      159. Reinisch W, Sandborn W, Panaccione R, Huang B, Pollack PF, Lazar A, Thakkar RB. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013 Jul; 19(8):1700-9. PMID: 23665965.
        View in: PubMed
      160. Sandborn W, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2014 Jan; 146(1):96-109.e1. PMID: 23770005.
        View in: PubMed
      161. Sandborn W, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63. PMID: 23730956.
        View in: PubMed
      162. Sandborn W, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2014 Jan; 146(1):85-95. PMID: 23735746.
        View in: PubMed
      163. Afif W, Sandborn W, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun; 19(7):1384-9. PMID: 23535248.
        View in: PubMed
      164. Pola S, Fahmy M, Evans E, Tipps A, Sandborn W. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol. 2013 May; 108(5):857-8. PMID: 23644970.
        View in: PubMed
      165. Rieder F, Zimmermann EM, Remzi FH, Sandborn W. Crohn's disease complicated by strictures: a systematic review. Gut. 2013 Jul; 62(7):1072-84. PMID: 23626373.
        View in: PubMed
      166. Sinakos E, Samuel S, Enders F, Loftus EV, Sandborn W, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013 Apr; 19(5):1004-9. PMID: 23502353.
        View in: PubMed
      167. Herfarth HH, Katz JA, Hanauer SB, Sandborn W, Loftus EV, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9. PMID: 23511031.
        View in: PubMed
      168. Feagan BG, Sandborn W, D'Haens G, Pola S, McDonald JW, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):149-157.e2. PMID: 23528626.
        View in: PubMed
      169. Sandborn W, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials. J Crohns Colitis. 2013 Dec 15; 7(12):958-67. PMID: 23517933.
        View in: PubMed
      170. Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Löwenberg M, Jairath V, Travis SP, Sandborn W, Feagan BG, D'Haens GR. Biosimilars in IBD: hope or expectation? Gut. 2013 Jun; 62(6):803-7. PMID: 23503043.
        View in: PubMed
      171. Sandborn W, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin. 2013 May; 29(5):483-93. PMID: 23438483.
        View in: PubMed
      172. Mayer L, Sandborn W, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar; 63(3):442-50. PMID: 23461895.
        View in: PubMed
      173. Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn W, Loftus EV, Kappelman MD, Lewis JD, Parkos CA, Sartor RB. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):677-82. PMID: 23448796.
        View in: PubMed
      174. Abboud R, Pardi DS, Tremaine WJ, Kammer PP, Sandborn W, Loftus EV. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis. 2013 Mar; 19(3):550-3. PMID: 23380937.
        View in: PubMed
      175. Fahmy M, Shabaik A, Sandborn W. Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):E57-8. PMID: 22552963.
        View in: PubMed
      176. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn W. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014 Mar; 63(3):433-41. PMID: 23436336.
        View in: PubMed
      177. Sandborn W, Travis S, Ballard D. Reply: budesonide. Gastroenterology. 2013 Mar; 144(3):e23-4. PMID: 23357061.
        View in: PubMed
      178. Velayos FS, Kahn JG, Sandborn W, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun; 11(6):654-66. PMID: 23357488.
        View in: PubMed
      179. Kisiel JB, Yab TC, Nazer Hussain FT, Taylor WR, Garrity-Park MM, Sandborn W, Loftus EV, Wolff BG, Smyrk TC, Itzkowitz SH, Rubin DT, Zou H, Mahoney DW, Ahlquist DA. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54. PMID: 23347191.
        View in: PubMed
      180. Relling MV, Gardner EE, Sandborn W, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013 Apr; 93(4):324-5. PMID: 23422873.
        View in: PubMed
      181. Gentile NM, Abdalla AA, Khanna S, Smyrk TC, Tremaine WJ, Faubion WA, Kammer PP, Sandborn W, Loftus EV, Pardi DS. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol. 2013 Feb; 108(2):256-9. PMID: 23295275.
        View in: PubMed
      182. Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn W, Panaccione R. Deep remission: a new concept? Dig Dis. 2012; 30 Suppl 3:107-11. PMID: 23295700.
        View in: PubMed
      183. Sandborn W. The future of inflammatory bowel disease therapy: where do we go from here? Dig Dis. 2012; 30 Suppl 3:140-4. PMID: 23295705.
        View in: PubMed
      184. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn W. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012 Dec; 107(12):1770-6. PMID: 23211844.
        View in: PubMed
      185. Sandborn W, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013 Jan; 37(2):204-13. PMID: 23173821.
        View in: PubMed
      186. Lichtenstein GR, Hanauer SB, Sandborn W. Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2012 Nov; 8(11 Suppl 8):1-20. PMID: 24847181.
        View in: PubMed
      187. Sandborn W, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28. PMID: 23075178.
        View in: PubMed
      188. Levesque BG, Sandborn W. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet. 2012 Dec 1; 380(9857):1887-8. PMID: 23063315.
        View in: PubMed
      189. Sandborn W, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013 Jan; 108(1):90-8. PMID: 23044768.
        View in: PubMed
      190. Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn W. Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013 Mar; 58(3):797-806. PMID: 23053885.
        View in: PubMed
      191. D'Haens G, Feagan B, Colombel JF, Sandborn W, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012 Dec; 143(6):1461-9. PMID: 23000597.
        View in: PubMed
      192. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn W, Loftus EV. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012 Nov; 107(11):1693-701. PMID: 22945286.
        View in: PubMed
      193. Baumgart DC, Sandborn W. Crohn's disease. Lancet. 2012 Nov 3; 380(9853):1590-605. PMID: 22914295.
        View in: PubMed
      194. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn W. Ulcerative colitis. Lancet. 2012 Nov 3; 380(9853):1606-19. PMID: 22914296.
        View in: PubMed
      195. Sandborn W, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16; 367(7):616-24. PMID: 22894574.
        View in: PubMed
      196. Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn W. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):49-54.e1. PMID: 22902762.
        View in: PubMed
      197. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn W. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22. PMID: 22890223.
        View in: PubMed
      198. Sandborn W, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov; 143(5):1218-26.e1-2. PMID: 22892337.
        View in: PubMed
      199. Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera-Nieves J, Chang JT, Evans E, Docherty M, Talamini M, Sandborn W. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1315-1325.e4. PMID: 22835577.
        View in: PubMed
      200. Ordás I, Feagan BG, Sandborn W. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Oct; 10(10):1079-87; quiz e85-6. PMID: 22813440.
        View in: PubMed
      201. Mohabbat AB, Sandborn W, Loftus EV, Wiesner RH, Bruining DH. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012 Sep; 36(6):569-74. PMID: 22779779.
        View in: PubMed
      202. Schreiber S, Reinisch W, Colombel JF, Sandborn W, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013 Apr 1; 7(3):213-21. PMID: 22704916.
        View in: PubMed
      203. Lichtenstein GR, Rutgeerts P, Sandborn W, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012 Jul; 107(7):1051-63. PMID: 22613901.
        View in: PubMed
      204. D'Haens G, Sandborn W, Barrett K, Hodgson I, Streck P. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012 Jul; 107(7):1064-77. PMID: 22565161.
        View in: PubMed
      205. Fahmy M, Ramamoorthy S, Hata T, Sandborn W. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012 May; 107(5):794-5. PMID: 22552250.
        View in: PubMed
      206. Sands BE, Sandborn W, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology. 2012 Aug; 143(2):356-64.e1. PMID: 22549092.
        View in: PubMed
      207. Sandborn W, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4. PMID: 22504093.
        View in: PubMed
      208. Samuel S, Bruining DH, Loftus EV, Becker B, Fletcher JG, Mandrekar JN, Zinsmeister AR, Sandborn W. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1253-9. PMID: 22503995.
        View in: PubMed
      209. Kane SV, Horst S, Sandborn W, Becker B, Neis B, Moscandrew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012 Dec; 18(12):2203-8. PMID: 22419661.
        View in: PubMed
      210. Ordás I, Mould DR, Feagan BG, Sandborn W. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr; 91(4):635-46. PMID: 22357456.
        View in: PubMed
      211. Rutgeerts P, Van Assche G, Sandborn W, Wolf DC, Geboes K, Colombel JF, Reinisch W. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012 May; 142(5):1102-1111.e2. PMID: 22326435.
        View in: PubMed
      212. Hommes D, Colombel JF, Emery P, Greco M, Sandborn W. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012 Feb; 6 Suppl 2:S224-34. PMID: 22463929.
        View in: PubMed
      213. Sandborn W. Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol (N Y). 2012 Feb; 8(2):117-9. PMID: 22485079.
        View in: PubMed
      214. Pineton de Chambrun GP, Sandborn W. IBD in 2011: Advances in IBD management--towards a tailored approach. Nat Rev Gastroenterol Hepatol. 2012 Feb; 9(2):70-2. PMID: 22230905.
        View in: PubMed
      215. Nguyen DL, Sandborn W, Loftus EV, Larson DW, Fletcher JG, Becker B, Mandrekar J, Harmsen WS, Bruining DH. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):400-4. PMID: 22155562.
        View in: PubMed
      216. Ford AC, Khan KJ, Sandborn W, Hanauer SB, Moayyedi P. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9. PMID: 22083024.
        View in: PubMed
      217. Sandborn W, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb; 142(2):257-65.e1-3. PMID: 22062358.
        View in: PubMed
      218. Colombel JF, Feagan BG, Sandborn W, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012 Feb; 18(2):349-58. PMID: 22021134.
        View in: PubMed
      219. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn W. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42. PMID: 21997563.
        View in: PubMed
      220. Ordás I, Feagan BG, Sandborn W. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011 Dec; 60(12):1754-63. PMID: 21997558.
        View in: PubMed
      221. Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn W. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2012 Jul; 18(7):1240-8. PMID: 21928375.
        View in: PubMed
      222. Ford AC, Khan KJ, Sandborn W, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec; 106(12):2070-7; quiz 2078. PMID: 21894226.
        View in: PubMed
      223. Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn W, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PMID: 21844919.
        View in: PubMed
      224. Sandborn W, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56. PMID: 21848857.
        View in: PubMed
      225. Levesque BG, Sandborn W. Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease. Inflamm Bowel Dis. 2012 Apr; 18(4):795-6. PMID: 21739537.
        View in: PubMed
      226. Samuel S, Loftus EV, Sandborn W. Henoch-schönlein purpura in an adult mimicking Crohn's disease and pyoderma gangrenosum. Dig Dis Sci. 2011 Jul; 56(7):2205-6. PMID: 21249449.
        View in: PubMed
      227. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn W. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201. PMID: 21723220.
        View in: PubMed
      228. Peyrin-Biroulet L, Cieza A, Sandborn W, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012 Feb; 61(2):241-7. PMID: 21646246.
        View in: PubMed
      229. Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn W, Pollack PF, Zhou Q, Robinson AM. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17. PMID: 21645018.
        View in: PubMed
      230. Sandborn W, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):670-678.e3. PMID: 21642014.
        View in: PubMed
      231. Bruining DH, Loftus EV, Ehman EC, Siddiki HA, Nguyen DL, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Sandborn W, Fletcher JG. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):679-683.e1. PMID: 21621641.
        View in: PubMed
      232. Reinisch W, Sandborn W, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11. PMID: 21484965.
        View in: PubMed
      233. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn W, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26. PMID: 21472012.
        View in: PubMed
      234. Garrity-Park M, Loftus EV, Sandborn W, Smyrk TC. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis. 2012 Feb; 18(2):275-83. PMID: 21425209.
        View in: PubMed
      235. Kisiel JB, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn W. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis. 2012 Feb; 18(2):226-35. PMID: 21416564.
        View in: PubMed
      236. Billioud V, Sandborn W, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011 Apr; 106(4):674-84. PMID: 21407178.
        View in: PubMed
      237. Ford AC, Sandborn W, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660. PMID: 21407183.
        View in: PubMed
      238. Sandborn W. Why innovation in inflammatory bowel disease drug development will impact your practice. Clin Gastroenterol Hepatol. 2011 Mar; 9(3):211-3. PMID: 21338946.
        View in: PubMed
      239. Siddiki H, Fletcher JG, Hara AK, Kofler JM, McCollough CH, Fidler JL, Guimaraes L, Huprich JE, Sandborn W, Loftus EV, Mandrekar J, Bruining DH. Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel. Inflamm Bowel Dis. 2011 Mar; 17(3):778-86. PMID: 20848546.
        View in: PubMed
      240. Peyrin-Biroulet L, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn W. Perianal Crohn's disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012 Jan; 18(1):43-8. PMID: 21351216.
        View in: PubMed
      241. Bruining DH, Siddiki HA, Fletcher JG, Sandborn W, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Evans PE, Faubion WA, Hanson KA, Ingle SB, Pardi DS, Schroeder KW, Tremaine WJ, Loftus EV. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis. 2012 Feb; 18(2):219-25. PMID: 21337477.
        View in: PubMed
      242. Bruining DH, Sandborn W. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2011 May; 9(5):395-9. PMID: 21277392.
        View in: PubMed
      243. Relling MV, Gardner EE, Sandborn W, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011 Mar; 89(3):387-91. PMID: 21270794.
        View in: PubMed
      244. Levesque BG, Hanson KA, Sandborn W. Reversal of multifocal low- and high-grade dysplasia in patients with an ileoanal pouch. Gastroenterology. 2011 Mar; 140(3):1107-8; author reply 1108-9. PMID: 21272556.
        View in: PubMed
      245. Feagan BG, Sandborn W, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar; 33(5):541-50. PMID: 21223344.
        View in: PubMed
      246. Reinisch W, Sandborn W, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7. PMID: 21209123.
        View in: PubMed
      247. Sandborn W, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011 Jan; 17(1):141-51. PMID: 20848500.
        View in: PubMed
      248. Thia K, Faubion WA, Loftus EV, Persson T, Persson A, Sandborn W. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis. 2011 Jan; 17(1):105-11. PMID: 20629100.
        View in: PubMed
      249. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn W, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb; 106(2):214-23; quiz 224. PMID: 21157441.
        View in: PubMed
      250. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn W, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11. PMID: 21104734.
        View in: PubMed
      251. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn W. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011 Jan; 33(2):194-202. PMID: 21114791.
        View in: PubMed
      252. Pariente B, Cosnes J, Danese S, Sandborn W, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011 Jun; 17(6):1415-22. PMID: 21560202.
        View in: PubMed
      253. Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn W. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93. PMID: 21083671.
        View in: PubMed
      254. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn W, Colombel JF, Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213. PMID: 21045814.
        View in: PubMed
      255. Samuel S, Loftus EV, Sandborn W. The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis. Aliment Pharmacol Ther. 2010 Nov; 32(9):1207-9. PMID: 21039684.
        View in: PubMed
      256. Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn W. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010 Nov; 16(11):1912-21. PMID: 20848486.
        View in: PubMed
      257. Sandborn W, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, Plevy S, Stokkers P, Travis S, Van Assche G, Baumgart DC, Targan SR. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010 Nov; 59(11):1485-92. PMID: 20947884.
        View in: PubMed
      258. Levesque BG, Sandborn W. Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2011 Jun; 17(6):1443-4. PMID: 21560204.
        View in: PubMed
      259. Sandborn W. State-of-the-art: Immunosuppression and biologic therapy. Dig Dis. 2010; 28(3):536-42. PMID: 20926883.
        View in: PubMed
      260. Thia KT, Loftus EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn W. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011 Jun; 17(6):1257-64. PMID: 20878712.
        View in: PubMed
      261. Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn W, Loftus EV, Larson DW. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg. 2010 Dec; 14(12):1859-65; discussion 1865-6. PMID: 20872084.
        View in: PubMed
      262. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn W. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011 Jan; 17(1):471-8. PMID: 20725943.
        View in: PubMed
      263. Thia KT, Sandborn W, Harmsen WS, Zinsmeister AR, Loftus EV. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010 Oct; 139(4):1147-55. PMID: 20637205.
        View in: PubMed
      264. Holubar SD, Cima RR, Sandborn W, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010; (6):CD001176. PMID: 20556748.
        View in: PubMed
      265. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn W. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93. PMID: 20491747.
        View in: PubMed
      266. Sandborn W, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):688-695.e2. PMID: 20451663.
        View in: PubMed
      267. Colombel JF, Sandborn W, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15; 362(15):1383-95. PMID: 20393175.
        View in: PubMed
      268. Oussalah A, Chevaux JB, Fay R, Sandborn W, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010 May; 105(5):1142-9. PMID: 20389296.
        View in: PubMed
      269. Sandborn W, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1. PMID: 20363366.
        View in: PubMed
      270. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn W. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9. PMID: 19714757.
        View in: PubMed
      271. Panaccione R, Colombel JF, Sandborn W, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Jun; 31(12):1296-309. PMID: 20298496.
        View in: PubMed
      272. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn W. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010 Jul; 105(7):1574-82. PMID: 20234346.
        View in: PubMed
      273. Sandborn W. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Dig Dis. 2009; 27 Suppl 1:80-4. PMID: 20203501.
        View in: PubMed
      274. Garrity-Park MM, Loftus EV, Sandborn W, Bryant SC, Smyrk TC. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010 Jul; 105(7):1610-9. PMID: 20160714.
        View in: PubMed
      275. Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn W. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May; 105(5):1133-9. PMID: 20145610.
        View in: PubMed
      276. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn W. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010 Feb; 59(2):141-7. PMID: 20176633.
        View in: PubMed
      277. Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn W. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9. PMID: 20117244.
        View in: PubMed
      278. Guimarães LS, Fidler JL, Fletcher JG, Bruining DH, Huprich JE, Siddiki H, Sandborn W, Loftus EV, Pardi DS, McCollough CH. Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis. 2010 Feb; 16(2):226-32. PMID: 19637359.
        View in: PubMed
      279. Vermeire S, Schreiber S, Sandborn W, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010 Apr; 8(4):357-63. PMID: 20096379.
        View in: PubMed
      280. Sandborn W, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. PMID: 20064514.
        View in: PubMed
      281. Malireddy K, Larson DW, Sandborn W, Loftus EV, Faubion WA, Pardi DS, Qin R, Gullerud RE, Cima RR, Wolff B, Dozois EJ. Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg. 2010 Jan; 145(1):42-7. PMID: 20083753.
        View in: PubMed
      282. Peyrin-Biroulet L, Cieza A, Sandborn W, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010 Jan; 16(1):15-22. PMID: 19610077.
        View in: PubMed
      283. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn W. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb; 105(2):289-97. PMID: 19861953.
        View in: PubMed
      284. D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S, Sandborn W. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1599-604. PMID: 19653291.
        View in: PubMed
      285. Sandborn W, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3. PMID: 19766640.
        View in: PubMed
      286. Colombel JF, Sandborn W, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009 Sep; 15(9):1308-19. PMID: 19434735.
        View in: PubMed
      287. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn W. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. PMID: 19408340.
        View in: PubMed
      288. Ravi K, Chari ST, Vege SS, Sandborn W, Smyrk TC, Loftus EV. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009 Sep; 15(9):1326-30. PMID: 19235915.
        View in: PubMed
      289. Manabe N, Cremonini F, Camilleri M, Sandborn W, Burton DD. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther. 2009 Nov 1; 30(9):930-6. PMID: 19678812.
        View in: PubMed
      290. Toedter GP, Blank M, Lang Y, Chen D, Sandborn W, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2768-73. PMID: 19672253.
        View in: PubMed
      291. Velayos FS, Sandborn W. Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride? Am J Gastroenterol. 2009 Aug; 104(8):2097-9. PMID: 19661939.
        View in: PubMed
      292. Sandborn W, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520. PMID: 19596014.
        View in: PubMed
      293. Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, Johnson CD, Bruining DH, Loftus EV, Sandborn W, Pardi DS, Mandrekar JN. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol. 2009 Jul; 193(1):113-21. PMID: 19542402.
        View in: PubMed
      294. Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, Barlow JM, Solem CA, Sandborn W, Loftus EV. CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom Imaging. 2009 Jul; 34(4):467-75. PMID: 18551336.
        View in: PubMed
      295. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn W. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009 Oct; 104(10):2524-33. PMID: 19532125.
        View in: PubMed
      296. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn W, Parenti D, Lee K, Reinisch W. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36. PMID: 19130617.
        View in: PubMed
      297. Peyrin-Biroulet L, Colombel JF, Sandborn W. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol. 2009 Oct; 7(10):1139. PMID: 19465159.
        View in: PubMed
      298. Hanson KA, Loftus EV, Harmsen WS, Diehl NN, Zinsmeister AR, Sandborn W. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis. 2009 May; 15(5):772-7. PMID: 19107782.
        View in: PubMed
      299. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn W. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009 Aug; 30(3):210-26. PMID: 19392858.
        View in: PubMed
      300. Colombel JF, Sandborn W, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9. PMID: 19352339.
        View in: PubMed
      301. Loftus EV, Friedman HS, Delgado DJ, Sandborn W. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis. 2009 Apr; 15(4):566-75. PMID: 19143006.
        View in: PubMed
      302. Garrity-Park MM, Loftus EV, Sandborn W, Bryant SC, Smyrk TC. MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut. 2009 Sep; 58(9):1226-33. PMID: 19251712.
        View in: PubMed
      303. Baumgart DC, Lowder JN, Targan SR, Sandborn W, Frankel MB. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol. 2009 Apr; 104(4):868-76. PMID: 19240707.
        View in: PubMed
      304. Colombel JF, Schwartz DA, Sandborn W, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009 Jul; 58(7):940-8. PMID: 19201775.
        View in: PubMed
      305. Lichtenstein GR, Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484. PMID: 19174807.
        View in: PubMed
      306. Jones J, Chen LS, Baudhuin L, Peterson S, Harmsen WS, Zinsmeister AR, McConnell J, Sandborn W. Relationships between C-reactive protein concentration and genotype in healthy volunteers. Clin Chem Lab Med. 2009; 47(1):20-5. PMID: 19072030.
        View in: PubMed
      307. Sandborn W. The future of inflammatory bowel disease care. Rev Gastroenterol Disord. 2009; 9(3):E69-77. PMID: 19898267.
        View in: PubMed
      308. Kamm MA, Lichtenstein GR, Sandborn W, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan; 15(1):1-8. PMID: 18671232.
        View in: PubMed
      309. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn W. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009 Jan; 15(1):17-24. PMID: 18668682.
        View in: PubMed
      310. Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn W, Loftus EV. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis. 2008 Dec; 14(12):1701-6. PMID: 18623171.
        View in: PubMed
      311. Thia KT, Sandborn W, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31. PMID: 18786111.
        View in: PubMed
      312. Thia KT, Loftus EV, Sandborn W, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008 Dec; 103(12):3167-82. PMID: 19086963.
        View in: PubMed
      313. Wang TC, Cominelli F, Fleischer DE, Gordon JM, Glickman RM, Limsui D, McQuaid KR, Montrose M, Pasricha PJ, Powell DW, Rowe WA, Sandborn W, Todisco A. AGA Institute Future Trends Committee report: the future of gastroenterology training programs in the United States. Gastroenterology. 2008 Nov; 135(5):1764-89.e2. PMID: 19009690.
        View in: PubMed
      314. Sandborn W. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008 Nov; 135(5):1442-7. PMID: 18848556.
        View in: PubMed
      315. Sandborn W. Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S232-3. PMID: 18816658.
        View in: PubMed
      316. Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn W. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008 Nov; 6(11):1218-24. PMID: 18799360.
        View in: PubMed
      317. Panaccione R, Rutgeerts P, Sandborn W, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Sep 15; 28(6):674-88. PMID: 18532990.
        View in: PubMed
      318. Feagan BG, Panaccione R, Sandborn W, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9. PMID: 18848553.
        View in: PubMed
      319. Sandborn W, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008 Oct; 135(4):1130-41. PMID: 18706417.
        View in: PubMed
      320. Peyrin-Biroulet L, Desreumaux P, Sandborn W, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008 Jul 5; 372(9632):67-81. PMID: 18603161.
        View in: PubMed
      321. Sandborn W. Certolizumab Pegol for Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2008 Jul; 4(7):467-8. PMID: 21960919.
        View in: PubMed
      322. Peloquin JM, Pardi DS, Sandborn W, Fletcher JG, McCollough CH, Schueler BA, Kofler JA, Enders FT, Achenbach SJ, Loftus EV. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2008 Aug; 103(8):2015-22. PMID: 18564113.
        View in: PubMed
      323. Loftus EV, Delgado DJ, Friedman HS, Sandborn W. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008 Jul; 103(7):1737-45. PMID: 18564126.
        View in: PubMed
      324. Solem CA, Loftus EV, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn W. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008 Aug; 68(2):255-66. PMID: 18513722.
        View in: PubMed
      325. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn W, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008 Jun; 6(6):644-53. PMID: 18550004.
        View in: PubMed
      326. Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn W, Vatn MH, Warren B, Riddell RH. Indeterminate colitis: a review of the concept--what's in a name? Inflamm Bowel Dis. 2008 Jun; 14(6):850-7. PMID: 18213696.
        View in: PubMed
      327. Sands BE, Sandborn W, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9. PMID: 18602921.
        View in: PubMed
      328. Feagan BG, Sandborn W, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008 Apr 9; 299(14):1690-7. PMID: 18398081.
        View in: PubMed
      329. Sandborn W. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008 Apr; 42(4):338-44. PMID: 18277908.
        View in: PubMed
      330. Lichtenstein GR, Kamm MA, Sandborn W, Lyne A, Joseph RE. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008 Jun 1; 27(11):1094-102. PMID: 18363894.
        View in: PubMed
      331. Sandborn W. Initial combination therapy in early Crohn's disease. Lancet. 2008 Feb 23; 371(9613):635-6. PMID: 18295013.
        View in: PubMed
      332. Kamm MA, Lichtenstein GR, Sandborn W, Schreiber S, Lees K, Barrett K, Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008 Jul; 57(7):893-902. PMID: 18272546.
        View in: PubMed
      333. Garrity-Park MM, Loftus EV, Bryant SC, Sandborn W, Smyrk TC. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008 Feb; 103(2):407-15. PMID: 18289203.
        View in: PubMed
      334. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn W, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr; 134(4):929-36. PMID: 18294633.
        View in: PubMed
      335. Sandborn W. Mucosal healing in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(4):271-2. PMID: 19107101.
        View in: PubMed
      336. Velayos FS, Sandborn W. Positioning biologic therapy for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2007 Dec; 9(6):521-7. PMID: 18377806.
        View in: PubMed
      337. Hanauer SB, Sandborn W, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34. PMID: 18080055.
        View in: PubMed
      338. Feagan BG, Sandborn W, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007 Dec; 102(12):2737-46. PMID: 18042106.
        View in: PubMed
      339. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn W. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5. PMID: 17567869.
        View in: PubMed
      340. Cima RR, Anderson KJ, Larson DW, Dozois EJ, Hassan I, Sandborn W, Loftus EV, Pemberton JH. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis. 2007 Oct; 13(10):1266-70. PMID: 17567877.
        View in: PubMed
      341. Sandborn W, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007 Oct 1; 26(7):987-1003. PMID: 17877506.
        View in: PubMed
      342. Reinisch W, Sandborn W, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007 Sep; 13(9):1135-40. PMID: 17476675.
        View in: PubMed
      343. Winter TA, Sandborn W, de Villiers WJ, Schreiber S. Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol. 2007 Sep; 3(5):683-94. PMID: 20477019.
        View in: PubMed
      344. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22. PMID: 17920064.
        View in: PubMed
      345. Mahadevan U, Sandborn W, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12. PMID: 17764676.
        View in: PubMed
      346. Sandborn W, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):228-38. PMID: 17634458.
        View in: PubMed
      347. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn W. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50. PMID: 17634459.
        View in: PubMed
      348. Sandborn W, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007 Jul 15; 26(2):205-15. PMID: 17593066.
        View in: PubMed
      349. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn W, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39. PMID: 17631151.
        View in: PubMed
      350. Tremaine WJ, Timmons LJ, Loftus EV, Pardi DS, Sandborn W, Harmsen WS, Thapa P, Zinsmeister AR. Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther. 2007 Jun 15; 25(12):1435-41. PMID: 17539983.
        View in: PubMed
      351. Camilleri M, Sandborn W, Kolars JC, Murray JA, Poterucha JJ, Roberts L, Sinicrope FA, Wang KK. A moveable feast. Clin Gastroenterol Hepatol. 2007 Jun; 5(6):646-7. PMID: 17544990.
        View in: PubMed
      352. Baumgart DC, Sandborn W. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12; 369(9573):1641-57. PMID: 17499606.
        View in: PubMed
      353. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV, Sandborn W, Wolff BG, Pemberton JH. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007 May; 204(5):956-62; discussion 962-3. PMID: 17481518.
        View in: PubMed
      354. Sandborn W, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38. PMID: 17470824.
        View in: PubMed
      355. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn W. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007 May; 132(5):1672-83. PMID: 17484865.
        View in: PubMed
      356. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Sandborn W. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007 Mar; 13(3):254-61. PMID: 17206702.
        View in: PubMed
      357. Feagan BG, Reinisch W, Rutgeerts P, Sandborn W, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802. PMID: 17324131.
        View in: PubMed
      358. Sandborn W, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9. PMID: 17299059.
        View in: PubMed
      359. Limsui D, Pardi DS, Camilleri M, Loftus EV, Kammer PP, Tremaine WJ, Sandborn W. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):175-81. PMID: 17206699.
        View in: PubMed
      360. Hanauer SB, Sandborn W. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3. PMID: 17303600.
        View in: PubMed
      361. Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn W. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007 Apr; 102(4):829-36. PMID: 17222314.
        View in: PubMed
      362. Desai D, Faubion WA, Sandborn W. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007 Feb 1; 25(3):247-55. PMID: 17217454.
        View in: PubMed
      363. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn W. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):95-102. PMID: 17234558.
        View in: PubMed
      364. Hanauer SB, Sandborn W. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2. PMID: 17392632.
        View in: PubMed
      365. Sandborn W. Clinical perspectives in Crohn's disease: now and in the future. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S1-2. PMID: 17392634.
        View in: PubMed
      366. Sandborn W. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S23-35. PMID: 17392636.
        View in: PubMed
      367. Sandborn W. A new treatment option for ulcerative colitis. Rev Gastroenterol Disord. 2007; 7(2):106-7. PMID: 17597673.
        View in: PubMed
      368. Sandborn W. Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y). 2007 Jan; 3(1):16-7. PMID: 21960772.
        View in: PubMed
      369. D'Haens G, Sandborn W, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86. PMID: 17258735.
        View in: PubMed
      370. Tung J, Loftus EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ, Harmsen WS, Sandborn W, Faubion WA. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006 Dec; 12(12):1093-100. PMID: 17119382.
        View in: PubMed
      371. Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn W. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007 Apr; 56(4):504-8. PMID: 17135309.
        View in: PubMed
      372. Colombel JF, Sandborn W, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65. PMID: 17241859.
        View in: PubMed
      373. Kamm MA, Sandborn W, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):66-75; quiz 432-3. PMID: 17241860.
        View in: PubMed
      374. Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA, Sandborn W, Loftus EV, Harmsen WS. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology. 2006 Dec; 241(3):787-95. PMID: 17032911.
        View in: PubMed
      375. Laing AW, Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn W. Microscopic colitis is not associated with cholecystectomy or appendectomy. Inflamm Bowel Dis. 2006 Aug; 12(8):708-11. PMID: 16917225.
        View in: PubMed
      376. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ, Munkholm P, Sandborn W. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006 Aug; 12(8):669-76. PMID: 16917220.
        View in: PubMed
      377. Sands BE, Kilgore KM, Bloomfeld RS, Sandborn W. Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice. J Clin Gastroenterol. 2006 Aug; 40(7):587-91. PMID: 16917398.
        View in: PubMed
      378. Sands BE, Sandborn W, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9. PMID: 16825929.
        View in: PubMed
      379. Rutgeerts P, Sandborn W, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):888-93. PMID: 16797249.
        View in: PubMed
      380. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn W. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006 Jun; 130(7):1941-9. PMID: 16762617.
        View in: PubMed
      381. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn W. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30. PMID: 16678077.
        View in: PubMed
      382. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn W. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. PMID: 16606351.
        View in: PubMed
      383. Sandborn W. What's new: innovative concepts in inflammatory bowel disease. Colorectal Dis. 2006 May; 8 Suppl 1:3-9. PMID: 16594957.
        View in: PubMed
      384. Schreiber S, Sandborn W. CLASSIC-I study the efficacy of adalimumab. Gastroenterology. 2006 May; 130(6):1929-30. PMID: 16697761.
        View in: PubMed
      385. Colombel JF, Solem CA, Sandborn W, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006 Nov; 55(11):1561-7. PMID: 16648154.
        View in: PubMed
      386. Pardi DS, Sandborn W. Systematic review: the management of pouchitis. Aliment Pharmacol Ther. 2006 Apr 15; 23(8):1087-96. PMID: 16611268.
        View in: PubMed
      387. Van Assche G, Sandborn W, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006 Nov; 55(11):1568-74. PMID: 16603634.
        View in: PubMed
      388. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, Munkholm P, Sandborn W. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006 Apr; 130(4):1039-46. PMID: 16618397.
        View in: PubMed
      389. Feagan BG, Sandborn W, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006 Mar 1; 23(5):617-28. PMID: 16480401.
        View in: PubMed
      390. Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn W, Loftus EV, Harmsen WS, Crownhart BS. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology. 2006 Feb; 238(2):505-16. PMID: 16436815.
        View in: PubMed
      391. Hanauer SB, Sandborn W, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591. PMID: 16472588.
        View in: PubMed
      392. Sandborn W, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006 Feb; 4(2):203-11. PMID: 16469681.
        View in: PubMed
      393. Jess T, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Munkholm P, Sandborn W. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006 Sep; 55(9):1248-54. PMID: 16423890.
        View in: PubMed
      394. Chopra A, Pardi DS, Loftus EV, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn W. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006 Jan; 12(1):29-32. PMID: 16374255.
        View in: PubMed
      395. Sandborn W. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S15-21. PMID: 16378006.
        View in: PubMed
      396. Hanauer SB, Sandborn W, Vakil N, Katz PO, Talley NJ, Rex DK, Hawes RH, Guda NM, Freeman ML, Keeffe EB, Balart LA. Best of DDW 2006. Rev Gastroenterol Disord. 2006; 6(3):153-89. PMID: 16957658.
        View in: PubMed
      397. Sandborn W. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord. 2006; 6(2):97-105. PMID: 16699478.
        View in: PubMed
      398. Rutgeerts P, Sandborn W, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8; 353(23):2462-76. PMID: 16339095.
        View in: PubMed
      399. Moolsintong P, Loftus EV, Chari ST, Egan LJ, Tremaine WJ, Sandborn W. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005 Dec; 11(12):1080-4. PMID: 16306770.
        View in: PubMed
      400. Egan LJ, Sandborn W. Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2005 Dec; 7(6):485-91. PMID: 16313879.
        View in: PubMed
      401. Sandborn W, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 3; 353(18):1912-25. PMID: 16267322.
        View in: PubMed
      402. Hanauer SB, Sandborn W, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85. PMID: 16279903.
        View in: PubMed
      403. Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn W, Steinhart AH. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8. PMID: 16254479.
        View in: PubMed
      404. Isaacs KL, Lewis JD, Sandborn W, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S3-12. PMID: 16254481.
        View in: PubMed
      405. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn W. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005 Oct; 100(10):2239-47. PMID: 16181376.
        View in: PubMed
      406. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn W. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Aug; 11(8):707-12. PMID: 16043984.
        View in: PubMed
      407. Sandborn W, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7. PMID: 16086715.
        View in: PubMed
      408. Larson DW, Dozois E, Sandborn W, Cima R. Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis. Surg Endosc. 2005 Sep; 19(9):1284-7. PMID: 16132322.
        View in: PubMed
      409. Toruner M, Harewood GC, Loftus EV, Sandborn W, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2005 May; 11(5):428-34. PMID: 15867581.
        View in: PubMed
      410. Mahadevan U, Kane S, Sandborn W, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8. PMID: 15771759.
        View in: PubMed
      411. Pardi DS, Sandborn W. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005 Mar; 54(3):321-2. PMID: 15710974.
        View in: PubMed
      412. Feagan BG, Sandborn W, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84. PMID: 15709987.
        View in: PubMed
      413. Hanauer S, Sandborn W, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71. PMID: 15709986.
        View in: PubMed
      414. Sandborn W. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord. 2005; 5(1):10-8. PMID: 15741928.
        View in: PubMed
      415. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn W. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005 Jan; 54(1):91-6. PMID: 15591511.
        View in: PubMed
      416. Sandborn W. Inflammatory bowel disease: a new combination therapy for pouchitis. Rev Gastroenterol Disord. 2005; 5(2):110. PMID: 15976743.
        View in: PubMed
      417. Sandborn W, Pardi DS. Clinical management of pouchitis. Gastroenterology. 2004 Dec; 127(6):1809-14. PMID: 15578518.
        View in: PubMed
      418. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn W, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004 Nov 11; 351(20):2069-79. PMID: 15537905.
        View in: PubMed
      419. Sandborn W, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9. PMID: 15447761.
        View in: PubMed
      420. Sandborn W, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004 Oct; 53(10):1485-93. PMID: 15361500.
        View in: PubMed
      421. Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn W, Egan LJ. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005 Feb; 312(2):537-45. PMID: 15388785.
        View in: PubMed
      422. Velayos FS, Sandborn W. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Sep; 10(5):657-60. PMID: 15472531.
        View in: PubMed
      423. Sandborn W, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology. 2004 Sep; 127(3):990-3. PMID: 15362055.
        View in: PubMed
      424. Sandborn W, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut. 2004 Sep; 53(9):1366-73. PMID: 15306602.
        View in: PubMed
      425. Panaccione R, Sandborn W. Medical therapy of Crohn disease. Curr Opin Gastroenterol. 2004 Jul; 20(4):351-9. PMID: 15703664.
        View in: PubMed
      426. Sandborn W, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut. 2004 Jun; 53(6):780-2. PMID: 15138201.
        View in: PubMed
      427. Loftus CG, Egan LJ, Sandborn W. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):141-69, vii. PMID: 15177532.
        View in: PubMed
      428. Sandborn W, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98. PMID: 15142198.
        View in: PubMed
      429. Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn W. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004 May; 99(5):878-83. PMID: 15128354.
        View in: PubMed
      430. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn W. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004 May; 10(3):207-14. PMID: 15290913.
        View in: PubMed
      431. Egan LJ, Sandborn W. Advances in the treatment of Crohn's disease. Gastroenterology. 2004 May; 126(6):1574-81. PMID: 15168368.
        View in: PubMed
      432. Matzke GM, Kang AS, Dozois EJ, Sandborn W. Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis Colon Rectum. 2004 May; 47(5):782-6. PMID: 15037928.
        View in: PubMed
      433. Sandborn W. Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm Bowel Dis. 2004 Feb; 10 Suppl 1:S35-7. PMID: 15168829.
        View in: PubMed
      434. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn W. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan; 126(1):19-31. PMID: 14699483.
        View in: PubMed
      435. Thomas CW, Weinshenker BG, Sandborn W. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Jan; 10(1):28-31. PMID: 15058523.
        View in: PubMed
      436. Solem CA, Loftus EV, Tremaine WJ, Sandborn W. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004 Jan; 99(1):97-101. PMID: 14687149.
        View in: PubMed
      437. Sandborn W. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004; 4(4):167-74. PMID: 15580151.
        View in: PubMed
      438. Sandborn W. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S25-33. PMID: 15583528.
        View in: PubMed
      439. Sandborn W. Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S1-5. PMID: 14697912.
        View in: PubMed
      440. Sandborn W. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec; 5(6):501-5. PMID: 14602060.
        View in: PubMed
      441. Sandborn W, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003 Nov; 98(11):2372-82. PMID: 14638336.
        View in: PubMed
      442. Sandborn W, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30. PMID: 14598268.
        View in: PubMed
      443. Loftus EV, Achenbach SJ, Sandborn W, Tremaine WJ, Oberg AL, Melton LJ. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003 Nov; 1(6):465-73. PMID: 15017646.
        View in: PubMed
      444. Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn W. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003 Oct; 98(10):2239-44. PMID: 14572574.
        View in: PubMed
      445. Wold PB, Fletcher JG, Johnson CD, Sandborn W. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology. 2003 Oct; 229(1):275-81. PMID: 12944602.
        View in: PubMed
      446. Sandborn W, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8. PMID: 12891539.
        View in: PubMed
      447. Sandborn W, Feagan BG. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003 Aug 1; 18(3):263-77. PMID: 12895211.
        View in: PubMed
      448. Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn W. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003 Jul; 9(4):237-45. PMID: 12902847.
        View in: PubMed
      449. Kane SV, Sandborn W, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. PMID: 12818275.
        View in: PubMed
      450. Sandborn W, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 1; 17(11):1355-64. PMID: 12786629.
        View in: PubMed
      451. Elson CO, Sartor RB, Targan SR, Sandborn W. Challenges in IBD Research: updating the scientific agendas. Inflamm Bowel Dis. 2003 May; 9(3):137-53. PMID: 12792219.
        View in: PubMed
      452. Mahadevan U, Sandborn W. Diagnosis and management of pouchitis. Gastroenterology. 2003 May; 124(6):1636-50. PMID: 12761722.
        View in: PubMed
      453. Sandborn W. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology. 2003 Apr; 124(4):1140-5. PMID: 12671907.
        View in: PubMed
      454. Loftus CG, Loftus EV, Sandborn W. Cyclosporin for refractory ulcerative colitis. Gut. 2003 Feb; 52(2):172-3. PMID: 12524395.
        View in: PubMed
      455. Sandborn W. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):105-17. PMID: 12617886.
        View in: PubMed
      456. Sandborn W, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42. PMID: 12492730.
        View in: PubMed
      457. Sandborn W. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002 Dec; 97(12):2939-41. PMID: 12492172.
        View in: PubMed
      458. Sandborn W, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72. PMID: 12492177.
        View in: PubMed
      459. Pardi DS, Ramnath VR, Loftus EV, Tremaine WJ, Sandborn W. Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol. 2002 Nov; 97(11):2829-33. PMID: 12425555.
        View in: PubMed
      460. Mahadevan U, Loftus EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn W. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002 Sep; 8(5):311-6. PMID: 12479645.
        View in: PubMed
      461. Solem CA, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Sandborn W. Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. Am J Gastroenterol. 2002 Sep; 97(9):2300-5. PMID: 12358248.
        View in: PubMed
      462. Loftus EV, Crowson CS, Sandborn W, Tremaine WJ, O'Fallon WM, Melton LJ. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002 Aug; 123(2):468-75. PMID: 12145800.
        View in: PubMed
      463. Kane SV, Schoenfeld P, Sandborn W, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002 Aug; 16(8):1509-17. PMID: 12182751.
        View in: PubMed
      464. Ricart E, Taylor WR, Loftus EV, O'Kane D, Weinshilboum RM, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn W. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol. 2002 Jul; 97(7):1763-8. PMID: 12135032.
        View in: PubMed
      465. Sandborn W, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002 May; 122(6):1592-608. PMID: 12016425.
        View in: PubMed
      466. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn W, Loftus EV. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002 May; 8(3):186-91. PMID: 11979139.
        View in: PubMed
      467. Pardi DS, Smyrk TC, Tremaine WJ, Sandborn W. Microscopic colitis: a review. Am J Gastroenterol. 2002 Apr; 97(4):794-802. PMID: 12003412.
        View in: PubMed
      468. Mahadevan U, Loftus EV, Tremaine WJ, Sandborn W. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr; 97(4):910-4. PMID: 12008668.
        View in: PubMed
      469. Ullman TA, Loftus EV, Kakar S, Burgart LJ, Sandborn W, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol. 2002 Apr; 97(4):922-7. PMID: 12008669.
        View in: PubMed
      470. Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn W. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr; 122(4):875-80. PMID: 11910338.
        View in: PubMed
      471. Loftus EV, Sandborn W. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):1-20. PMID: 12122726.
        View in: PubMed
      472. Sandborn W, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30. PMID: 11832465.
        View in: PubMed
      473. Feagan BG, Sandborn W. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Rev Gastroenterol Disord. 2002; 2 Suppl 2:S9-15. PMID: 12478239.
        View in: PubMed
      474. Dayharsh GA, Loftus EV, Sandborn W, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002 Jan; 122(1):72-7. PMID: 11781282.
        View in: PubMed
      475. Loftus EV, Schoenfeld P, Sandborn W. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002 Jan; 16(1):51-60. PMID: 11856078.
        View in: PubMed
      476. Mahadevan U, Sandborn W. Evolving medical therapies for Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):471-6. PMID: 11696284.
        View in: PubMed
      477. Schwartz DA, Pemberton JH, Sandborn W. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001 Nov 20; 135(10):906-18. PMID: 11712881.
        View in: PubMed
      478. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sandborn W. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology. 2001 Nov; 121(5):1064-72. PMID: 11677197.
        View in: PubMed
      479. Sandborn W, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94. PMID: 11677200.
        View in: PubMed
      480. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM, Sandborn W. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001 Nov; 49(5):656-64. PMID: 11600468.
        View in: PubMed
      481. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn W. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001 Nov; 49(5):665-70. PMID: 11600469.
        View in: PubMed
      482. Loftus EV, Sandborn W. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology. 2001 Nov; 121(5):1239-42. PMID: 11677218.
        View in: PubMed
      483. Faubion WA, Loftus EV, Sandborn W, Freese DK, Perrault J. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr. 2001 Sep; 33(3):296-300. PMID: 11593125.
        View in: PubMed
      484. Tremaine WJ, Sandborn W, Loftus EV, Kenan ML, Petterson TM, Zinsmeister AR, Silverstein MD. A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol. 2001 Aug; 96(8):2401-6. PMID: 11513181.
        View in: PubMed
      485. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn W. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001 Aug; 121(2):255-60. PMID: 11487534.
        View in: PubMed
      486. Patel AH, Loftus EV, Murray JA, Harmsen WS, Zinsmeister AR, Sandborn W. Cigarette smoking and celiac sprue: a case-control study. Am J Gastroenterol. 2001 Aug; 96(8):2388-91. PMID: 11513179.
        View in: PubMed
      487. Sandborn W, Loftus EV, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001 Aug; 7(3):192-201. PMID: 11515844.
        View in: PubMed
      488. Yang SK, Loftus EV, Sandborn W. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis. 2001 Aug; 7(3):260-70. PMID: 11515854.
        View in: PubMed
      489. Pike MG, Franklin CL, Mays DC, Lipsky JJ, Lowry PW, Sandborn W. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl. 2001 Jun 5; 757(1):1-9. PMID: 11419732.
        View in: PubMed
      490. Decker GA, Loftus EV, Pasha TM, Tremaine WJ, Sandborn W. Crohn's disease of the esophagus: clinical features and outcomes. Inflamm Bowel Dis. 2001 May; 7(2):113-9. PMID: 11383583.
        View in: PubMed
      491. Sandborn W. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001 May; 48(5):591-2. PMID: 11302950.
        View in: PubMed
      492. Sandborn W, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8. PMID: 11313302.
        View in: PubMed
      493. Pardi DS, Loftus EV, Tremaine WJ, Sandborn W. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology. 2001 May; 120(6):1483-4. PMID: 11313319.
        View in: PubMed
      494. Coulie B, Camilleri M, Bharucha AE, Sandborn W, Burton D. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther. 2001 May; 15(5):653-63. PMID: 11328259.
        View in: PubMed
      495. Levy AM, Yamazaki K, Van Keulen VP, Burgart LJ, Sandborn W, Phillips SF, Kephart GM, Gleich GJ, Leiferman KM. Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis. Am J Gastroenterol. 2001 May; 96(5):1522-8. PMID: 11374693.
        View in: PubMed
      496. Sandborn W. Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S9-16. PMID: 11380043.
        View in: PubMed
      497. Sands BE, Tremaine WJ, Sandborn W, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8. PMID: 11383595.
        View in: PubMed
      498. Sandborn W. Strategies targeting tumor necrosis factor in Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):170-2. PMID: 11475128.
        View in: PubMed
      499. Sandborn W. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):201-4. PMID: 11475136.
        View in: PubMed
      500. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43. PMID: 11280528.
        View in: PubMed
      501. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn W. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001 Mar; 96(3):722-9. PMID: 11280541.
        View in: PubMed
      502. Mahadevan U, Sandborn W. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis. 2001 Feb; 7(1):38-42. PMID: 11233659.
        View in: PubMed
      503. Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, Sandborn W. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol. 2000 Dec; 95(12):3463-8. PMID: 11151878.
        View in: PubMed
      504. Sandborn W, Faubion WA. Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep. 2000 Dec; 2(6):440-5. PMID: 11079044.
        View in: PubMed
      505. Egan LJ, Tremaine WJ, Mays DC, Lipsky JJ, Sandborn W. Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis. 2000 Nov; 6(4):286-9. PMID: 11149561.
        View in: PubMed
      506. Limburg PJ, Ahlquist DA, Sandborn W, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000 Oct; 95(10):2831-7. PMID: 11051356.
        View in: PubMed
      507. Loftus EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn W. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000 Sep; 95(9):2308-12. PMID: 11007233.
        View in: PubMed
      508. Sandborn W. Steroid-dependent Crohn's disease. Can J Gastroenterol. 2000 Sep; 14 Suppl C:17C-22C. PMID: 11023556.
        View in: PubMed
      509. Bulois P, Tremaine WJ, Maunoury V, Gambiez L, Hafraoui S, Leteurtre L, Cortot A, Sandborn W, Colombel JF, Desreumaux P. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis. 2000 Aug; 6(3):157-64. PMID: 10961587.
        View in: PubMed
      510. Sandborn W. Therapy for Crohn disease. Curr Opin Gastroenterol. 2000 Jul; 16(4):318-23. PMID: 17031095.
        View in: PubMed
      511. Pardi DS, Tremaine WJ, Sandborn W, Loftus EV, Poland GA, Harmsen WS, Zinsmeister AR, Melton LJ. Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol. 2000 Jun; 95(6):1480-5. PMID: 10894583.
        View in: PubMed
      512. Faubion WA, Sandborn W. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology. 2000 Mar; 118(3):630-1. PMID: 10702217.
        View in: PubMed
      513. Loftus EV, Silverstein MD, Sandborn W, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000 Mar; 46(3):336-43. PMID: 10673294.
        View in: PubMed
      514. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn W, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15. PMID: 10701144.
        View in: PubMed
      515. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2):CD000545. PMID: 10796557.
        View in: PubMed
      516. Sandborn W, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev. 2000; (2):CD001176. PMID: 10796613.
        View in: PubMed
      517. Egan LJ, Sandborn W, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999 Dec; 13(12):1597-604. PMID: 10594394.
        View in: PubMed
      518. Ricart E, Sandborn W. Infliximab for the treatment of fistulas in patients with Crohn'S disease. Gastroenterology. 1999 Nov; 117(5):1247-8. PMID: 10535892.
        View in: PubMed
      519. Lowry PW, Weaver AL, Tremaine WJ, Sandborn W. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999 Nov; 5(4):239-45. PMID: 10579116.
        View in: PubMed
      520. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn W, Lipsky JJ, McKean DJ. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999 Sep 10; 274(37):26448-53. PMID: 10473604.
        View in: PubMed
      521. Sandborn W, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35. PMID: 10464128.
        View in: PubMed
      522. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn W. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999 Aug; 117(2):429-32. PMID: 10419926.
        View in: PubMed
      523. Louvet B, Buisine MP, Desreumaux P, Tremaine WJ, Aubert JP, Porchet N, Capron M, Cortot A, Colombel JF, Sandborn W. Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis. 1999 Aug; 5(3):174-81. PMID: 10453373.
        View in: PubMed
      524. Egan LJ, Sandborn W, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999 Aug; 5(3):167-73. PMID: 10453372.
        View in: PubMed
      525. Lowry PW, Sandborn W, Lipsky JJ. Mycophenolate mofetil for Crohn's disease? Lancet. 1999 Jul 3; 354(9172):3-4. PMID: 10406354.
        View in: PubMed
      526. Silverstein MD, Loftus EV, Sandborn W, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999 Jul; 117(1):49-57. PMID: 10381909.
        View in: PubMed
      527. Panaccione R, Sandborn W. The appendix in ulcerative colitis: a not so innocent bystander. Gastroenterology. 1999 Jul; 117(1):272-3. PMID: 10381940.
        View in: PubMed
      528. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn W. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999 Jun; 116(6):1505-6. PMID: 10391741.
        View in: PubMed
      529. Lowry PW, Sandborn W. A comparison of budesonide and mesalamine for active Crohn's disease. Gastroenterology. 1999 May; 116(5):1263. PMID: 10220523.
        View in: PubMed
      530. Sandborn W. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol. 1999 May; 94(5):1161-71. PMID: 10235187.
        View in: PubMed
      531. Harewood GC, Loftus EV, Tefferi A, Tremaine WJ, Sandborn W. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis. 1999 May; 5(2):98-103. PMID: 10338378.
        View in: PubMed
      532. Pardi DS, Tremaine WJ, Sandborn W, Loftus EV, Poland GA, Melton LJ. Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflamm Bowel Dis. 1999 May; 5(2):104-6. PMID: 10338379.
        View in: PubMed
      533. Sandborn W, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33. PMID: 10338381.
        View in: PubMed
      534. Tremaine WJ, Sandborn W. Practice guidelines for inflammatory bowel disease: an instrument for assessment. Mayo Clin Proc. 1999 May; 74(5):495-501. PMID: 10319083.
        View in: PubMed
      535. Panaccione R, Sandborn W. Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology. 1999 Apr; 116(4):1001-2; discussion 1002-3. PMID: 10092326.
        View in: PubMed
      536. Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK, Sandborn W, Larusso NF, Lindor KD. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 1999 Mar; 44(3):602-7. PMID: 10080157.
        View in: PubMed
      537. Sandborn W, McLeod R, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis. 1999 Feb; 5(1):33-9. PMID: 10028447.
        View in: PubMed
      538. Pardi DS, Loftus EV, Tremaine WJ, Sandborn W, Alexander GL, Balm RK, Gostout CJ. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc. 1999 Feb; 49(2):153-7. PMID: 9925691.
        View in: PubMed
      539. Egan LJ, Sandborn W, Mays DC, Tremaine WJ, Fauq AH, Lipsky JJ. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999 Jan; 65(1):29-39. PMID: 9951428.
        View in: PubMed
      540. Muñoz-Juarez M, Pemberton JH, Sandborn W, Tremaine WJ, Dozois RR. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum. 1999 Jan; 42(1):117-20. PMID: 10211531.
        View in: PubMed
      541. Matteson EL, Orces CH, Duffy J, Lipsky JJ, Pike MG, Sandborn W. Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. Arthritis Rheum. 1999 Jan; 42(1):186-7. PMID: 9920030.
        View in: PubMed
      542. Egan LJ, Sandborn W. Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov; 115(5):1295-6. PMID: 9797390.
        View in: PubMed
      543. Egan LJ, Sandborn W, Mays DC, Tremaine WJ, Lipsky JJ. Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision. Aliment Pharmacol Ther. 1998 Jul; 12(7):679-84. PMID: 9701533.
        View in: PubMed
      544. Sandborn W, Loftus EV, Ahlquist DA. Association of primary sclerosing cholangitis and colorectal cancer in patients with ulcerative colitis: is it true and does it matter? Gastroenterology. 1998 Jul; 115(1):236-7. PMID: 9649486.
        View in: PubMed
      545. Green JT, Rhodes J, Thomas GA, Evans BK, Feyerabend C, Russell MA, Sandborn W. Nicotine carbomer enemas--pharmacokinetics of a revised formulation. Ital J Gastroenterol Hepatol. 1998 Jun; 30(3):260-5. PMID: 9759592.
        View in: PubMed
      546. Loftus EV, Silverstein MD, Sandborn W, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998 Jun; 114(6):1161-8. PMID: 9609752.
        View in: PubMed
      547. Egan LJ, Sandborn W. Drug therapy of inflammatory bowel disease. Drugs Today (Barc). 1998 May; 34(5):431-46. PMID: 15010706.
        View in: PubMed
      548. Kaditis AG, Perrault J, Sandborn W, Landers CJ, Zinsmeister AR, Targan SR. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Apr; 26(4):386-92. PMID: 9552133.
        View in: PubMed
      549. Pardi DS, Tremaine WJ, Sandborn W, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998 Apr; 93(4):504-14. PMID: 9576439.
        View in: PubMed
      550. Loftus EV, Aguilar HI, Sandborn W, Tremaine WJ, Krom RA, Zinsmeister AR, Graziadei IW, Wiesner RH. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998 Mar; 27(3):685-90. PMID: 9500695.
        View in: PubMed
      551. Sandborn W. Inflammatory bowel disease and hereditary nonpolyposis colorectal cancer: is there a genetic link? Gastroenterology. 1998 Mar; 114(3):608-9. PMID: 9496956.
        View in: PubMed
      552. Nuako KW, Ahlquist DA, Sandborn W, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer. 1998 Mar 1; 82(5):822-6. PMID: 9486569.
        View in: PubMed
      553. Egan LJ, Sandborn W, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998 Mar; 93(3):442-8. PMID: 9517654.
        View in: PubMed
      554. Sandborn W. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998; 225:92-9. PMID: 9515759.
        View in: PubMed
      555. Sandborn W. Are short-chain fatty acid enemas effective for left-sided ulcerative colitis? Gastroenterology. 1998 Jan; 114(1):218-9. PMID: 9428236.
        View in: PubMed
      556. Tremaine WJ, Sandborn W, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 1997 Dec; 11(6):1041-6. PMID: 9663827.
        View in: PubMed
      557. Green JT, Thomas GA, Rhodes J, Williams GT, Evans BK, Russell MA, Feyerabend C, Rhodes P, Sandborn W. Nicotine enemas for active ulcerative colitis--a pilot study. Aliment Pharmacol Ther. 1997 Oct; 11(5):859-63. PMID: 9354193.
        View in: PubMed
      558. Compton RF, Sandborn W, Lawson GM, Sheets AJ, Mays DC, Zins BJ, Tremaine WJ, Lipsky JJ, Mahoney DW, Zinsmeister AR, Offord KP, Hurt RD, Evans BK, Green J. A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. Aliment Pharmacol Ther. 1997 Oct; 11(5):865-74. PMID: 9354194.
        View in: PubMed
      559. Sandborn W. A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology. 1997 Sep; 113(3):1042-3. PMID: 9288004.
        View in: PubMed
      560. Nyam DC, Pemberton JH, Sandborn W, Savcenko M. Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum. 1997 Aug; 40(8):971-2. PMID: 9269816.
        View in: PubMed
      561. Sandborn W. 6-MP metabolite levels: a potential guide to Crohn's disease therapy. Gastroenterology. 1997 Aug; 113(2):690-2. PMID: 9247497.
        View in: PubMed
      562. Sandborn W, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther. 1997 Aug; 11(4):663-71. PMID: 9305473.
        View in: PubMed
      563. Loftus EV, Tremaine WJ, Nelson RA, Shoemaker JD, Sandborn W, Phillips SF, Hasan Y. Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc. 1997 Jul; 72(7):616-20. PMID: 9212762.
        View in: PubMed
      564. Sandborn W. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997 May; 92(5):876-9. PMID: 9149205.
        View in: PubMed
      565. Zins BJ, Sandborn W, Mays DC, Lawson GM, McKinney JA, Tremaine WJ, Mahoney DW, Zinsmeister AR, Hurt RD, Offord KP, Lipsky JJ. Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. J Clin Pharmacol. 1997 May; 37(5):426-36. PMID: 9156375.
        View in: PubMed
      566. Green JT, Thomas GA, Rhodes J, Evans BK, Russell MA, Feyerabend C, Fuller GS, Newcombe RG, Sandborn W. Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. Clin Pharmacol Ther. 1997 Mar; 61(3):340-8. PMID: 9084459.
        View in: PubMed
      567. Sandborn W, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997 Mar 1; 126(5):364-71. PMID: 9054280.
        View in: PubMed
      568. Levy AM, Gleich GJ, Sandborn W, Tremaine WJ, Steiner BL, Phillips SF. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc. 1997 Feb; 72(2):117-23. PMID: 9033543.
        View in: PubMed
      569. Sandborn W. Erythropoietin for inflammatory bowel disease anemia. Gastroenterology. 1997 Feb; 112(2):660-1. PMID: 9024321.
        View in: PubMed
      570. Zins BJ, Sandborn W, McKinney JA, Mays DC, van Os EC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol. 1997 Jan; 37(1):38-46. PMID: 9048271.
        View in: PubMed
      571. Compton RF, Sandborn W, Yang H, Lindor NM, Tremaine WJ, Davis MD, Khalil AA, Tountas NA, Tyan DB, Landers CJ, Taylor KD, Viggiano TR, Matteson EL, Schroeter AL, Plevy SE, Cominelli F, Targan SR, Rotter JI. A new syndrome of Crohn's disease and pachydermoperiostosis in a family. Gastroenterology. 1997 Jan; 112(1):241-9. PMID: 8978365.
        View in: PubMed
      572. Loftus EV, Sandborn W, Lindor KD, Larusso NF. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis. 1997; 3(4):288-302. PMID: 23282876.
        View in: PubMed
      573. Sandborn W. Does the surgical failure rate, increased incidence of pouchitis, and recent findings of dysplasia in pouches deter you from recommending an ileal pouch-anal anastomosis for ulcerative colitis? Inflamm Bowel Dis. 1997; 3(3):239-40. PMID: 23282811.
        View in: PubMed
      574. Li X, Hamdy R, Sandborn W, Chi D, Dyer A. Long-term effects of antidepressants on balance, equilibrium, and postural reflexes. Psychiatry Res. 1996 Jul 31; 63(2-3):191-6. PMID: 8878315.
        View in: PubMed
      575. Van Os EC, Zins BJ, Sandborn W, Mays DC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut. 1996 Jul; 39(1):63-8. PMID: 8881811.
        View in: PubMed
      576. Loftus EV, Sandborn W, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology. 1996 May; 110(5):1496-502. PMID: 8613055.
        View in: PubMed
      577. Sandborn W, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996 May; 71(5):431-6. PMID: 8628021.
        View in: PubMed
      578. Van Os EC, McKinney JA, Zins BJ, Mays DC, Schriver ZH, Sandborn W, Lipsky JJ. Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Apr 26; 679(1-2):147-54. PMID: 8998554.
        View in: PubMed
      579. Sandborn W. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996 Mar; 91(3):423-33. PMID: 8633486.
        View in: PubMed
      580. Loftus EV, Sandborn W, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996 Feb; 110(2):432-40. PMID: 8566590.
        View in: PubMed
      581. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996 Feb; 38(2):234-9. PMID: 8801203.
        View in: PubMed
      582. Sandborn W, Tremaine WJ, Lawson GM. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol. 1996 Jan; 91(1):37-43. PMID: 8561141.
        View in: PubMed
      583. Egan LJ, Sandborn W. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc. 1996 Jan; 71(1):69-80. PMID: 8538238.
        View in: PubMed
      584. Zins BJ, Sandborn W, Penna CR, Landers CJ, Targan SR, Tremaine WJ, Wiesner RH, Dozois RR. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 Dec; 90(12):2177-81. PMID: 8540511.
        View in: PubMed
      585. Sandborn W, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology. 1995 Dec; 109(6):1808-17. PMID: 7498645.
        View in: PubMed
      586. Sandborn W. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology. 1995 Sep; 109(3):1001-3. PMID: 7657085.
        View in: PubMed
      587. Zins BJ, Sandborn W, Tremaine WJ. Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. Am J Gastroenterol. 1995 Sep; 90(9):1394-400. PMID: 7661156.
        View in: PubMed
      588. Sandborn W, Tremaine WJ, Batts KP, Pemberton JH, Rossi SS, Hofmann AF, Gores GJ, Phillips SF. Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci. 1995 Jul; 40(7):1474-83. PMID: 7628271.
        View in: PubMed
      589. Sandborn W, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 May; 90(5):740-7. PMID: 7733080.
        View in: PubMed
      590. Loftus EV, Sandborn W. Drug therapy for inflammatory bowel disease. Contemp Intern Med. 1995 Apr; 7(4):21-34. PMID: 10150344.
        View in: PubMed
      591. Sandborn W, Lawson GM, Cody TJ, Porayko MK, Hay JE, Gores GJ, Steers JL, Krom RA, Wiesner RH. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995 Jan; 21(1):70-6. PMID: 7528712.
        View in: PubMed
      592. Sandborn W. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994 Dec; 107(6):1856-60. PMID: 7958702.
        View in: PubMed
      593. Sandborn W, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994 Jun; 106(6):1429-35. PMID: 8194687.
        View in: PubMed
      594. Sandborn W, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994 May; 69(5):409-15. PMID: 8170189.
        View in: PubMed
      595. Sandborn W, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994 Apr; 19(4):925-32. PMID: 8138267.
        View in: PubMed
      596. Sandborn W, Gross JB, Larson DE, Phillips JK, Lindor KD. High-volume postobstructive choleresis after transhepatic external biliary drainage resolves with conversion to internal drainage. J Clin Gastroenterol. 1993 Jul; 17(1):42-5. PMID: 8409297.
        View in: PubMed
      597. Sandborn W, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol. 1993 May; 88(5):640-5. PMID: 8480724.
        View in: PubMed
      598. Sandborn W, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut. 1993 Feb; 34(2):242-6. PMID: 8432481.
        View in: PubMed
      599. Sandborn W, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc. 1992 Oct; 67(10):981-90. PMID: 1434859.
        View in: PubMed
      600. Sandborn W, Goldman DH, Lawson GM, Perrault J. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1992 Aug; 15(2):125-9. PMID: 1357126.
        View in: PubMed
      601. Sandborn W, Lawson GM, Krom RA, Wiesner RH. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology. 1992 Jun; 15(6):1086-91. PMID: 1592348.
        View in: PubMed
      602. Sandborn W, Strong RM, Forland SC, Chase RE, Cutler RE. The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration. J Clin Pharmacol. 1991 Jan; 31(1):76-80. PMID: 2045532.
        View in: PubMed
      603. Sandborn W, Forland SC, Cutler RE, Strong RM. Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. J Clin Pharmacol. 1990 Jun; 30(6):568-71. PMID: 2355107.
        View in: PubMed